Review Article
The Role of Intravenous Immunoglobulin Preparations in the Treatment of Systemic Sclerosis
Table 1
IVIG in patients with SSc.
| Author/year | Number of patients | Skin lesions | Results | Remarks |
| Bodemer et al. 1990 [6] | 1 | Only in the face | Myositis improvement | SSc-dermatomyositis overlap | Levy et al. 2000 [8] | 3 | dcSSc | Regression of skin score, disease stabilization | No changes in PM-Scl antibodies | Levy et al. 2004 [9] | 15 | 5 patients-lcSSc,10 patients-dcSSc | Decreased mRSS, changes in HAQ score | Very high skin score in patients with lcSSc | Nacci et al. 2007 [10] | 7 | 5 patients-limited SSc, 2 patients diffuse SSc | Decreased VAS, IAFD, mRSS after 6-month treatment | Effects on joints and skin | Asano et al. 2005 [11] | 1 | Fingers, hands, forearms, upper arms, face, chest, abdomen, lower legs, dorsum of the feet | Decreased mRSS | | Szekanecz et al. 2009 [12] | 1 | Disuse SSc, refractory to treatment | Good clinical effect | Combination of IVIG and plasmapheresis |
|
|